CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8+ T cells.
Zhou T, Hou X, Yan J, Li L, Xie Y, Bai W, Jiang W, Zou Y, Li X, Liu Z, Zhang Z, Xu B, Mao G, Wang Y, Gao S, Wang X, Zhao T, Wang H, Sun H, Zhang X, Yu J, Huang C, Liu J, Hao J.
Zhou T, et al. Among authors: hao j.
Gut. 2024 Nov 11;73(12):1984-1998. doi: 10.1136/gutjnl-2024-332371.
Gut. 2024.
PMID: 39187291